GSK taps experimental arthritis antibody to calm the cytokine storm hitting COVID-19 patients

Specifically, the U.K.-based Big Pharma says it has “identified” a monoclonal antibody from its pipeline, anti-GM-CSF (granulocyte macrophage colony-stimulating factor) otilimab, as a “potential treatment for patients who have been hospitalised with severe pulmonary complications related to COVID-19.”